Application of 68Ga-Pentixafor PET/CT for Thymoma
Chemokine Receptor CXCR4-targeting PET Imaging for Thymoma
1 other identifier
interventional
100
1 country
1
Brief Summary
Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for early_phase_1
Started Jun 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 22, 2023
CompletedFirst Submitted
Initial submission to the registry
October 11, 2023
CompletedFirst Posted
Study publicly available on registry
October 17, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedOctober 17, 2023
June 1, 2023
1.5 years
October 11, 2023
October 11, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
SUVmax and SUVmean
SUVsof focal lesions are measured on 68Ga-Pentixafor PET/CT. The SUVs of the blood pool and muscle are defined as the background activity on the condition that there is no focally hypermetabolic disease.
through study completion, an average of 1.5 years
Secondary Outcomes (4)
Diagnostic value
through study completion, an average of 1.5 years
Diagnostic value in special type of thymoma
through study completion, an average of 1.5 years
Diagnostic value in thymoma and other masses
through study completion, an average of 1.5 years
CXCR4 expression and SUV
through study completion, an average of 1.5 years
Study Arms (1)
68Ga-Pentixafor, PET/CT
EXPERIMENTALInject 68Ga-Pentixafor and then perform PET/CT scan.
Interventions
Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
Eligibility Criteria
You may qualify if:
- suspected or confirmed untreated thymoma patients
- signed written consent.
You may not qualify if:
- pregnancy
- breastfeeding
- known allergy against Pentixafor
- any medical condition that in the opinion of the investigator,may
- significantly interfere with study compliance.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Peking Union Medical College Hospitall, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, 100730, China
Related Publications (1)
Gao X, Peng X, Wang R, Qian Z, Zhou X, Zhu Z, Chen Y. An Occult Primary Thymic Mucosa-Associated Lymphoid Tissue Lymphoma With Sjogren's Syndrome Revealed by CXCR4 Targeted 68Ga-Pentixafor PET/CT. J Cell Mol Med. 2025 Feb;29(3):e70248. doi: 10.1111/jcmm.70248.
PMID: 39887860DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Zhaohui Zhu
Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 11, 2023
First Posted
October 17, 2023
Study Start
June 22, 2023
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
October 17, 2023
Record last verified: 2023-06
Data Sharing
- IPD Sharing
- Will not share